Compare Ginkgo Bioworks Holdings Inc (DNA) vs Newegg Commerce Inc (NEGG) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

NEGG trades at $11.69, down 2.66% today, with a bearish technical signal from moving averages but oversold RSI readings. The company shows improving fundamentals with revenue stabilizing around $1.4B and net losses narrowing significantly from -$59M in 2023 to -$4.88M in 2025. Recent earnings beats and strategic partnerships with Western Digital and HPE highlight operational progress, though negative operating cash flow and insider selling present concerns.

The outlook remains mixed with improving profitability trends but significant execution risks. Valuation appears reasonable with P/S of 0.18x, but analyst consensus target of $7.75 suggests 34% downside. Key risks include competitive e-commerce pressures and the need to sustain recent operational improvements amid challenging market conditions.